Why the study?
Does the semi-synthetic heparin analogue A73025 differ from heparin in its effects on platelet function and coagulation parameters?
Does the semi-synthetic heparin analogue A73025 differ from heparin in its effects on platelet function and coagulation parameters?
The semi-synthetic heparin analogue A73025 exhibits different effects on platelet aggregation and thrombin inhibition compared to standard heparin, despite similar anti-factor Xa activity.
Answers are grounded in this paper and cite their sources.
Distinct platelet effects in animals warrant caution extrapolating anti-Xa equivalence to practice; leaves open A73025's human role.
A comparison has been made of some effects of a semi-synthetic heparin analogue, A73025, and heparin upon platelet function. In several of the in vitro tests performed, such as their potentiating effects on ADP and adrenaline induced aggregation and their effects on the aggregation of washed platelets by activated factor X, heparin proved to be more potent than A73025. Following intravenous injection of twice the quantity of A73025, an equivalent anti-factor Xa activity was obtained, in the agreement with our previous studies. However, it was found that PRP containing heparin and A73025 with comparable anti-Factor Xa acitvity responded differently to the addition of thrombin, as A73025 barely inhibited thrombin induced aggregation. Similarly, A73025 had little effect on the dilute thrombin clotting time of plasma, following intravenous injection. Heparin and A73025 were neutralized to approximately the same degree by a crude PF4 preparation.
No takes yet. Share an insight, caveat, or question.
Michalski et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: